CD30 as a therapeutic target in adult haematological malignancies: Where are we now? - Institut Pierre Louis d'Epidémiologie et de Santé Publique Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) British Journal of Haematology Année : 2023

CD30 as a therapeutic target in adult haematological malignancies: Where are we now?

Résumé

CD30 is a transmembrane protein from the tumour necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms. CD30 is a particularly interesting treatment target because its levels are high in tumours but low in healthy tissues. Several therapeutic strategies targeting CD30 have been developed, including monoclonal antibodies, conjugated antibodies (combination of brentuximab vedotin with chemotherapy or immunotherapy), bispecific antibodies and cell and gene therapies, such as anti-CD30 CART cells in particular. We briefly review the biology of CD30 which makes it a good therapeutic target, and we describe all of the anti-CD30 therapies that have emerged to date.
Fichier principal
Vignette du fichier
Br J Haematol - 2023 - Veyri - CD30 as a therapeutic target in adult haematological malignancies Where are we now.pdf (1.23 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-04095716 , version 1 (12-05-2023)

Identifiants

Citer

Marianne Veyri, J. Spano, F. Le Bras, A. Marcelin, E. Todesco. CD30 as a therapeutic target in adult haematological malignancies: Where are we now?. British Journal of Haematology, inPress, ⟨10.1111/bjh.18841⟩. ⟨hal-04095716⟩
9 Consultations
27 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More